2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal of the American College of Cardiology（2022）

引用 0|浏览4

暂无评分

摘要

Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.

查看译文

关键词

ACC/AHA Clinical Practice Guidelines,ACE inhibitors,SGLT2 inhibitors,acute decompensated heart failure,angiotensin and neprilysin receptor antagonist,angiotensin receptor antagonist,atrial fibrillation,beta blockers,cardiac amyloidosis,cardiac failure,cardio-oncology,cardiogenic shock,cardiomyopathy,cardiomyopathy in pregnancy,chronic heart failure,congestive heart failure,diabetes,guideline-directed medical therapy,heart failure,heart failure rehabilitation,heart failure with mildly reduced ejection fraction,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,mineralocorticoid receptor antagonists,mitral regurgitation,palliative care,reduced ejection fraction,right heart pressure,sacubitril-valsartan,social determinants of health,sodium glucose co-transporter 2,systolic heart failure,valvular heart disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要